139P Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Background: Until recently, neoadjuvant therapy for HCC has been limited by a lack of effective approaches.Prior studies have shown that patients (pts) achieving major pathological response (MPR) with neoadjuvant therapy have improved recurrencefree survival (RFS) in early-stage hepatocellular carcinoma (HCC).This prospective study aimed to explore the efficacy and safety of TACE combined with lenvatinib and tislelizumab in high-risk resectable HCC pts.
Authors
- Yueyin Pan (ORCID: https://orcid.org/0000-0003-0532-5368)
- Yaojun Zhang (ORCID: https://orcid.org/0000-0002-9752-4729)
- S. H. Ngai
- Li Xu (ORCID: https://orcid.org/0000-0003-4405-1048)
- M. Chen (ORCID: https://orcid.org/0000-0002-4607-1440)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100768
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00